PDF(Pubmed)
Abstract：
Bioorthogonal transition metal catalysts (TMCs) transform therapeutically inactive molecules (pro-drugs) into active drug compounds. Inorganic nanoscaffolds protect and solubilize catalysts while offering a flexible design space for decoration with targeting elements and stimuli-responsive activity. These \"drug factories\" can activate pro-drugs in situ, localizing treatment to the disease site and minimizing off-target effects. Inorganic nanoscaffolds provide structurally diverse scaffolds for encapsulating TMCs. This ability to define the catalyst environment can be employed to enhance the stability and selectivity of the TMC, providing access to enzyme-like bioorthogonal processes. The use of inorganic nanomaterials as scaffolds TMCs and the use of these bioorthogonal nanozymes in vitro and in vivo applications will be discussed in this review.
摘要：
生物正交过渡金属催化剂(TMC)将治疗非活性分子(前药)转化为活性药物化合物。无机纳米支架保护和溶解催化剂，同时为具有靶向元素和刺激响应活性的装饰提供灵活的设计空间。这些“药物工厂”可以原位激活前药，将治疗定位到疾病部位，并最大限度地减少脱靶效应。无机纳米支架提供了用于封装TMC的结构多样的支架。这种限定催化剂环境的能力可用于增强TMC的稳定性和选择性。提供获得类酶生物正交过程。本文将讨论无机纳米材料作为支架TMCs的使用以及这些生物正交纳米酶在体外和体内的应用。
